Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AC Immune S.A.
(NQ:
ACIU
)
3.380
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
3.380
Bid (Size)
3.320 (13)
Ask (Size)
3.830 (1)
Prev. Close
3.380
Today's Range
3.380 - 3.380
52wk Range
2.200 - 5.140
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
September 23, 2024
Via
Benzinga
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
September 17, 2024
From
AC Immune SA
Via
GlobeNewswire
Performance
YTD
-27.93%
-27.93%
1 Month
+13.04%
+13.04%
3 Month
-2.87%
-2.87%
6 Month
+20.71%
+20.71%
1 Year
+32.03%
+32.03%
More News
Read More
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
August 28, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 06, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
July 31, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
July 25, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
July 16, 2024
From
AC Immune SA
Via
GlobeNewswire
RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 14, 2024
Via
Benzinga
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
May 31, 2024
Via
Benzinga
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
May 31, 2024
Via
Benzinga
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
May 28, 2024
From
AC Immune SA
Via
GlobeNewswire
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
May 23, 2024
Via
Benzinga
DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
May 15, 2024
Via
Benzinga
ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024
May 13, 2024
Via
InvestorPlace
Gold Down Over 1%; AC Immune Shares Spike Higher
May 13, 2024
Via
Benzinga
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13, 2024
Via
Benzinga
Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
May 13, 2024
Via
Benzinga
Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge
May 13, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?
May 13, 2024
Via
InvestorPlace
Why Is Safe & Green Development (SGD) Stock Down 5% Today?
May 13, 2024
Via
InvestorPlace
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Why Is AC Immune (ACIU) Stock Up 45% Today?
May 13, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
May 13, 2024
Via
InvestorPlace
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
May 13, 2024
From
AC Immune SA
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.